By Andrew Don2018-03-28T08:31:00
Glaxosmithkline (GSK) has agreed to take full control of its consumer healthcare joint venture from Novartis. It will buy the remaining 36.5% stake in the business, whose brands include Panadol and Sensodyne, for £9.2bn. It will also launch a strategic review of its nutrition products, including Horlicks to help fund ...
Already have an account? Sign in here
Already have an account? Sign in here
You’ve used up your article allowance